Tech Billionaire Sean Parker Funds Immunotherapy Cancer Institute With $250 Million
Announced on April 13, the grant aims to boost development of stronger cancer-fighting drugs while pulling together the top cancer centers, drugmakers, and other heads of the industry.
With a collaborative approach in mind, the Parker Institute was started back in July of 2015, hoping to create a sandbox effect among the top institutions; institutions such as: Memorial Sloan Kettering Cancer Center; Stanford Medicine; University of California, Los Angeles; University of California, San Francisco; University of Pennsylvania; and The University of Texas MD Anderson Cancer Center.
These leading cancer institutions will pool together roughly 300 scientists and researchers to ensure the sharing of discoveries and tools, with a common goal to quickly make major breakthroughs.
Combining the efforts of the researchers and leading cancer institutions, Parker plans to create a roadmap to funding projects to create, test, and experiment with patients at all six cancer centers each year.
“We’ll make progress against three or four cancer types in the next several years,” he said.
The loss of Parker’s late friend Laura Ziskin in 2011 helped him realize the need to overhaul cancer research, according to an interview with Reuters. Ziskin was a Hollywood producer known for such films as “Pretty Woman” and founder of Stand Up To Cancer.
“Losing Laura transformed me,” Parker told Reuters.
The American Cancer Society describes immunotherapy as treatment that uses certain parts of a person’s immune system to fight diseases such as cancer. This can be done in a couple of ways:
- Stimulating your own immune system to work harder or smarter to attack cancer cells
- Giving you immune system components, such as man-made immune system proteins
Some types of immunotherapy are also sometimes called biologic therapy or biotherapy.
Immunotherapy works better for some types of cancer than for others. It’s used by itself for some of these cancers, but for others it seems to work better when used with other types of treatment.
Parker believes initial treatments of immunotherapy will prove most effective; a method typically reserved until chemotherapy failure or other standard treatments wear off. However, the immune system is often weak after initial treatments and immunotherapy usually fails.
Focusing on patients, Parker said any profits will be put back into the institute, and plans to hold off on licensing new drugs or technologies until research proves they will maximize return of investments.
The Associated Press contributed to this report.